Yin Li Meets With Heads of Multinational Pharmaceutical Enterprises and Associations

People’s Financial News, March 21 — According to Beijing Daily, on the morning of March 21, Beijing Municipal Party Secretary Yin Li met with representatives from multinational pharmaceutical companies and industry associations. Yin Li stated that in recent years, the Chinese government has placed a high priority on public health and has made safeguarding people’s health a strategic focus for development. China has explored a path of healthcare reform suited to its national conditions, establishing the world’s largest medical insurance system, with significant improvements in overall public health levels. The average life expectancy of Beijing residents is nearly 84 years, and the infant mortality rate is 1.3‰. Beijing is the political, cultural, international exchange, and technological innovation center of China, as well as a hub for innovation and development in the biopharmaceutical industry. The pharmaceutical market is large, and research capabilities are strong. In recent years, policies supporting the entire industry chain have been continuously optimized to promote rapid development of the healthcare industry, with the industry scale exceeding one trillion yuan. Long-term engagement in China and deep roots in Beijing by multinational pharmaceutical companies and industry associations have made positive contributions to China’s health initiatives and the development of a healthy Beijing. They hope to deepen pharmaceutical collaboration and innovation with Beijing, promote the transformation and application of scientific and technological achievements, expand the use of artificial intelligence in drug discovery, clinical trials, and intelligent diagnostics, and enhance the level of integrated innovation in “AI + medicine.” They also aim to further increase investment and layout in Beijing, actively participate in the construction of international pharmaceutical innovation parks, jointly promote the development of the pharmaceutical industry, and introduce more innovative products and services that meet market and public health needs to benefit more patients. Additionally, they seek to strengthen international health exchanges and cooperation to contribute more to building a global community of health. Leaders from multinational pharmaceutical companies and associations, including Wu Sipuo, President and CEO of the U.S. Pharmaceutical Research and Manufacturers of America, Stefan Oschmann, Chairman of the Board of Roche Group, and Vas Narasimhan, CEO of Novartis Group, expressed that China has achieved significant progress in health and wellness. Beijing’s vibrant innovation ecosystem and booming industry provide ample opportunities for development. Looking ahead, they are confident and plan to further expand investment and business in Beijing, deepen cooperation in new drug R&D, clinical trials, and digital healthcare, and make greater contributions to the construction of a Healthy China and the improvement of public health and well-being.